Related Experiment Video
Updated: May 3, 2026
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
2.1K
Prognostic biomarkers in thyroid cancer.
Paula Soares1, Ricardo Celestino, Miguel Melo
1Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP), Rua Dr Roberto Frias s/n, 4200-465, Porto, Portugal, psoares@ipatimup.pt.
Virchows Archiv : an International Journal of Pathology
|February 4, 2014
Summary
Identifying reliable prognostic biomarkers for thyroid cancer is crucial. While clinical factors are established, genetic markers like BRAF mutations show potential, especially for radioactive iodine-refractory papillary thyroid carcinomas, requiring further research.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Thyroid carcinomas are common endocrine malignancies with generally good prognoses.
- However, 10-15% of papillary thyroid carcinomas (PTCs) become refractory to radioactive iodine therapy.
- There is a growing need for prognostic biomarkers to predict tumor behavior due to rising incidence.
Purpose of the Study:
- To explore the diagnostic and prognostic value of biomarkers in thyroid tumors.
- To identify reliable indicators for predicting the behavior of thyroid carcinomas.
- To assess the potential of genetic markers, such as BRAF mutations, in managing refractory cases.
Main Methods:
- Review of clinical and histopathological prognostic factors.
- Analysis of genetic information from thyroid tumors.
- Evaluation of BRAF mutation status in relation to clinico-pathological parameters.
Main Results:
- Clinical and histopathological factors remain the primary tools for diagnosis and prognosis.
- Few genetic markers have demonstrated standalone diagnostic or prognostic value.
- BRAF mutation may be valuable when combined with other parameters or in iodine-refractory tumors.
Conclusions:
- Further research is needed to validate potential biomarkers for thyroid cancer.
- BRAF mutation shows promise as a predictive biomarker, particularly for refractory PTC.
- Development of predictive biomarkers for therapeutic response is an ongoing area of investigation.
